|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
Nov 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study |
Dec 2023 |
Blood Advances |
Aplastic Anemia |
